In this issue:
Aspirin may protect against HBV-related HCC
High SVR with onsite HCV care delivered to PWID in OAT programmes
Nivolumab ± GS-4774 in virallysuppressed HBeAg– patients
DAAs improve survival in HCV-cirrhotic patients
Sofosbuvir/velpatasvir in HCV-infected patients with ESRD
Testing for NS5A RASs with newest retreatment regimes
Is HBV a risk factor for non-liver malignancy?
Low early discontinuation rates with second-generation DAAs
Increasing HCV treatment uptake amongst PWID in primary care
Regular HCC surveillance improves survival in HCV infection
Please login below to download this issue (PDF)